Status:
COMPLETED
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
19-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the potential for a PK drug-drug interaction when IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination. Safety and tolera...
Eligibility Criteria
Inclusion
- Agrees to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug
- Male participants agree not to donate sperm from Day -1 through 90 days after the last dose of study drug
Exclusion
- Is pregnant or breastfeeding
- Has another clinically significant medical conditions or laboratory abnormality(s)
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT01907724
Start Date
May 1 2013
End Date
August 1 2013
Last Update
January 26 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.